Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 2, 943–944 (1 December 2003) | doi:10.1038/nrd1258
Daptomycin
&
Abstract
In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
